{"product_id":"gild-ansoff-analysis","title":"(GILD) Gilead Sciences, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Ansoff Matrix Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Gilead Sciences, Inc. Ansoff Matrix Analysis maps growth options across market penetration, market development, product development, and diversification to support strategy, investment, or planning decisions. The page includes a genuine preview of the analysis so you can review style and substance before buying; purchase the full version to receive the complete ready-to-use report. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiktarvy HIV treatment share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiktarvy remains Gilead Sciences, Inc.'s core HIV brand, with 2024 sales of about $13.4 billion and HIV product revenue near $19.6 billion. Gilead uses it to deepen use in the United States, Europe, and other markets, supporting retention across a large, mature HIV base and strong prescriber loyalty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDescovy PrEP uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDescovy supports Gilead Sciences, Inc.'s prevention push in existing HIV markets, and it stays tied to treatment brands like Biktarvy and Odefsey across the care path. In the U.S., it remains the only FDA-approved PrEP option for cisgender men and transgender women at risk, which helps Gilead keep the same patient base as people switch or stay on therapy. That mix supports retention more than pure new-customer growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy HIV brand retention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead Sciences, Inc. keeps Genvoya, Odefsey, Truvada, Complera\/Eviplera, Stribild, and Atripla in the commercial HIV mix to defend its installed base. These 6 legacy brands help retain clinics, payers, and long-term patients already inside Gilead Sciences, Inc.’s system. That is market penetration: protecting existing demand, not chasing new categories.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHCV franchise defense\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGilead Sciences, Inc. uses Epclusa, Harvoni, Vosevi, Vemlidy, and Viread to defend share in hepatitis C and liver care, a classic market penetration move. In 2024, Gilead reported $28.8 billion in total revenue, so keeping this legacy franchise active still matters. The portfolio helps retain prescribers and patients already in its ecosystem, rather than chasing new disease areas.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDefends share with known brands\u003c\/li\u003e\n\u003cli\u003eKeeps HCV switch risk lower\u003c\/li\u003e\n\u003cli\u003eSupports repeat use in liver care\u003c\/li\u003e\n\u003cli\u003eUses an established revenue base\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCell therapy and oncology share building\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eYescarta, Tecartus, Trodelvy, and Zydelig deepen Gilead Sciences, Inc.'s reach in oncology and cell therapy, where Yescarta and Trodelvy are the main growth engines. In 2024, Yescarta delivered $1.7 billion in product sales and Trodelvy $1.3 billion, showing strong use in major cancer centers and supporting specialist adoption in high-value settings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eYescarta: $1.7 billion sales\u003c\/li\u003e\n\u003cli\u003eTrodelvy: $1.3 billion sales\u003c\/li\u003e\n\u003cli\u003eTecartus expands hematologic reach\u003c\/li\u003e\n\u003cli\u003eZydelig supports legacy oncology presence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead’s HIV Franchise Wins by Defending, Not Expanding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead Sciences, Inc. drives market penetration by pushing Biktarvy, Descovy, and older HIV brands deeper into an already large base; HIV product revenue was about $19.6 billion in 2024, with Biktarvy at about $13.4 billion. That shows retention, switching, and share defense more than new market creation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003e2024 Sales\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiktarvy\u003c\/td\u003e\n\u003ctd\u003e$13.4B\u003c\/td\u003e\n\u003ctd\u003eCore HIV share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYescarta\u003c\/td\u003e\n\u003ctd\u003e$1.7B\u003c\/td\u003e\n\u003ctd\u003eOncology depth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrodelvy\u003c\/td\u003e\n\u003ctd\u003e$1.3B\u003c\/td\u003e\n\u003ctd\u003eSpecialist use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix framework for analyzing Gilead Sciences, Inc.’s growth strategy across products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Gilead Sciences Ansoff Matrix snapshot to quickly align growth strategy across existing and new drugs, markets, and partnerships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable Gilead sources that link each Ansoff growth path to traceable references for faster, defensible strategy and due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. and Europe HIV expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead Sciences, Inc. can grow HIV sales by pushing approved brands into more U.S. and European markets, not by changing the product mix. The HIV franchise already anchors the business, with Biktarvy and Descovy driving adoption, so wider country coverage can lift volume with low R\u0026amp;D spend. That is classic market development: same therapies, broader geography.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational hepatitis C rollout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead Sciences, Inc. can use Epclusa, Harvoni, Vosevi, Vemlidy, and Viread to push hepatitis C and liver-disease sales into more international markets, a classic market development move with existing drugs.\u003c\/p\u003e\n\u003cp\u003eWHO says about 50 million people live with chronic hepatitis C worldwide, with roughly 1.0 million new infections each year, so demand still exists outside Gilead Sciences, Inc.'s core markets.\u003c\/p\u003e\n\u003cp\u003eThat gives Gilead Sciences, Inc. room to expand access and win new country launches without needing a new molecule.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Veklury access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeklury extends Gilead Sciences, Inc. beyond HIV and liver disease into acute-care COVID-19 treatment, with approvals in more than 50 countries. Its IV use lets Gilead sell through hospitals and health systems already in its commercial footprint, expanding into new care settings without a new molecule. That makes it a clear market development move: same product, more geographies and treatment channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCell therapy geography expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eYescarta and Tecartus give Gilead Sciences, Inc. a clear cell therapy geography expansion path: both can scale in markets with approved CAR-T sites, leukapheresis capacity, and trained oncology teams. In 2024, Yescarta generated about $1.6 billion and Tecartus about $0.4 billion, showing real demand beyond the U.S. Gilead’s global commercial base helps widen country-level access where specialist centers already exist.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets countries with CAR-T centers\u003c\/li\u003e\n\u003cli\u003eUses Gilead's global sales footprint\u003c\/li\u003e\n\u003cli\u003eBuilds on Yescarta and Tecartus demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner-led entry into new geographies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGilead Sciences uses partner-led expansion to move approved science into new geographies faster, with alliances spanning Japan Tobacco, Janssen, Galapagos, and Merck. In FY2024, Gilead posted $28.8 billion in revenue, so even small gains in market reach can matter. This model fits markets where local registration, launch, and channel access need a local partner.\u003c\/p\u003e\n\u003cp\u003ePartners help Gilead turn one asset into multi-country sales without building a full direct footprint first. It also lowers execution risk in markets that need local regulatory know-how. One line: the deal network is a distribution tool, not just an R\u0026amp;D tool.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands reach across borders\u003c\/li\u003e\n\u003cli\u003eUses approved assets faster\u003c\/li\u003e\n\u003cli\u003eFits local launch-heavy markets\u003c\/li\u003e\n\u003cli\u003eLifts scale with less capital\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead’s Growth Play: Expand Proven Drugs Into New Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead Sciences, Inc. uses market development by taking approved drugs into more countries and care settings, not by changing the molecule. HIV, hepatitis C, COVID-19, and CAR-T products all fit this model.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$28.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYescarta\u003c\/td\u003e\n\u003ctd\u003e$1.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTecartus\u003c\/td\u003e\n\u003ctd\u003e$0.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCV cases\u003c\/td\u003e\n\u003ctd\u003e50M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eGilead Sciences, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full Ansoff Matrix report you'll get, covering market penetration, product development, market development, and diversification strategies for Gilead. Buy to unlock the full, editable version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiktarvy single-tablet innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiktarvy is Gilead Sciences, Inc.'s single-tablet HIV regimen and a core product in its mature HIV franchise. It brought in $13.4 billion in 2024 sales, showing how one-pill dosing still drives strong share in existing markets. This is product development in the Ansoff Matrix: Gilead keeps improving the same market with a simpler, stickier format.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeklury intravenous antiviral\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeklury (remdesivir) extends Gilead Sciences, Inc. beyond HIV into a branded antiviral for hospital-based COVID-19 care. The IV formulation fits product development: it uses Gilead Sciences, Inc.’s existing commercial and medical network, but with a newer therapy. In 2025, the drug still supports a non-HIV revenue stream after peak pandemic demand, helping diversify the portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrodelvy oncology expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrodelvy pushed Gilead Sciences, Inc. beyond antivirals and into oncology, where it reported about $1.3 billion in 2024 product sales. The drug expands Gilead Sciences, Inc. in treated cancer markets where it already sells specialist medicines, so this fits Product Development in the Ansoff Matrix. In 2025, Trodelvy remained a key growth driver in a high-growth solid-tumor area.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCAR-T portfolio build-out\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGilead Sciences, Inc. is building out CAR-T through Yescarta and Tecartus, two autologous cell therapies for blood cancers used in specialist centers. Yescarta is approved for large B-cell lymphomas, while Tecartus targets mantle cell lymphoma and B-cell precursor acute lymphoblastic leukemia, widening Gilead Sciences, Inc. beyond small-molecule and antiviral drugs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdvanced oncology platform, not just one asset\u003c\/li\u003e\n\u003cli\u003eSpecialist-center delivery raises clinical moat\u003c\/li\u003e\n\u003cli\u003eDeepens pipeline in blood cancer care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCollaborative pipeline advancement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGilead Sciences, Inc. uses collaborative pipeline advancement to turn its 12 named alliances with Arcus Biosciences, Pionyr Immunotherapeutics, Tizona Therapeutics, Tango Therapeutics, Jounce Therapeutics, Galapagos, Janssen, Japan Tobacco, Gadeta, Bristol-Myers Squibb, Dragonfly Therapeutics, and Merck into new therapies for current markets.\u003c\/p\u003e\n\u003cp\u003eThis is classic product development in the Ansoff Matrix: the Company keeps the same core markets in oncology, immunology, and related fields, but expands the menu of treatments through partnered R\u0026amp;D rather than solo build-out.\u003c\/p\u003e\n\u003cp\u003eThese deals matter because they spread scientific risk, add fresh assets to the pipeline, and speed access to areas where Gilead already sells or plans to sell. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12 active partners fuel pipeline depth\u003c\/li\u003e\n\u003cli\u003eFocus stays on existing therapeutic markets\u003c\/li\u003e\n\u003cli\u003ePartnerships cut discovery risk and time\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead Grows by Expanding Core Drugs and Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead Sciences, Inc. uses product development to deepen its core HIV and oncology franchises with newer formats and expanded labels. Biktarvy, Trodelvy, Veklury, and CAR-T assets like Yescarta and Tecartus show the same-market, new-product play. Partnered R\u0026amp;D also adds pipeline breadth without full solo risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024 Sales\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiktarvy\u003c\/td\u003e\n\u003ctd\u003e$13.4B\u003c\/td\u003e\n\u003ctd\u003eHIV core\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrodelvy\u003c\/td\u003e\n\u003ctd\u003e$1.3B\u003c\/td\u003e\n\u003ctd\u003eOncology growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology beyond antivirals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead Sciences, Inc. has moved well beyond HIV and hepatitis: Yescarta and Tecartus brought in about $2.0 billion in 2024 sales, and Trodelvy added about $1.3 billion, showing real oncology scale.\u003c\/p\u003e\n\u003cp\u003eThese drugs serve different patients, clinics, and payer rules, so the mix is true diversification into a new therapeutic area, not just a line extension.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell therapy market entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead Sciences, Inc. has moved beyond antivirals into cell therapy with Yescarta and Tecartus, targeting hematologic cancers in hospital and oncology-center settings. In fiscal 2025, the franchise generated about $1.9 billion, showing real diversification into a new product class. Yescarta alone has topped $1 billion in annual sales, proving scale in a highly specialized market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCOVID-19 treatment position\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeklury (remdesivir) gives Gilead Sciences, Inc. a pandemic-response antiviral that is separate from HIV and hepatitis C, so it broadens the company’s revenue base into acute infectious disease care. In 2025, Veklury stayed a key part of Gilead Sciences, Inc.'s non-HIV portfolio, used for hospitalized and high-risk COVID-19 patients. This is diversification in the Ansoff sense: the same drug platform reaches a new, time-sensitive market need, not just chronic-therapy demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePulmonary arterial hypertension and angina\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn 2025, Gilead Sciences, Inc. reported $28.8 billion in product sales, and Letairis and Ranexa showed its reach beyond antivirals into pulmonology and cardiology. Letairis addressed pulmonary arterial hypertension, while Ranexa treated chronic angina, so both tapped different prescribers, patients, and reimbursement paths. That diversification lowered dependence on one disease area, even as both faced generic pressure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLetairis: pulmonary arterial hypertension.\u003c\/li\u003e\n\u003cli\u003eRanexa: chronic angina.\u003c\/li\u003e\n\u003cli\u003eDifferent markets, prescribers, patients.\u003c\/li\u003e\n\u003cli\u003eLegacy diversification beyond antivirals.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSerious fungal infection therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmBisome, Gilead Sciences, Inc.'s liposomal amphotericin B, pushes the company into invasive fungal infection care, a non-core area next to HIV and liver disease. In 2025, Gilead Sciences, Inc. reported $28.8 billion in product sales, so this adds a smaller but real infectious-disease niche.\u003c\/p\u003e\n\u003cp\u003eThis diversification broadens Gilead Sciences, Inc. across more sub-specialties, and AmBisome helps reduce reliance on the biggest franchises. It also gives exposure to severe hospital-use antifungal therapy, where demand is tied to immunocompromised and ICU patients.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNon-core, but adjacent to infectious disease\u003c\/li\u003e\n\u003cli\u003eExpands beyond HIV and liver disease\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead’s Growth Engine Is Spreading Beyond Antivirals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead Sciences, Inc. is diversifying beyond antivirals through cell therapy, oncology, and hospital care. In fiscal 2025, Yescarta and Tecartus generated about $1.9 billion, while Trodelvy added about $1.3 billion, proving scale in a new therapeutic area. Veklury and AmBisome widen the mix further across acute infectious disease and antifungal care.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 sales\u003c\/th\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eYescarta\/Tecartus\u003c\/td\u003e\n\u003ctd\u003e~$1.9B\u003c\/td\u003e\n\u003ctd\u003eCell therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrodelvy\u003c\/td\u003e\n\u003ctd\u003e~$1.3B\u003c\/td\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVeklury\u003c\/td\u003e\n\u003ctd\u003eNot disclosed\u003c\/td\u003e\n\u003ctd\u003eCOVID-19\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191837630729,"sku":"gild-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/gild-ansoff-analysis.webp?v=1783678756","url":"https:\/\/dcfanalyst.com\/products\/gild-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}